✦ LIBER ✦

PCN98 COST-EFFECTIVENESS OF PROGNOSIS-BASED STRATEGIES TO SELECT WOMEN WITH BREAST CANCER FOR ADJUVANT CHEMOTHERAPY

✍ Scribed by Bonastre, J; Koscielny, S

Book ID: 122249370
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 72 KB
Volume: 12
Category: Article
ISSN: 1098-3015
DOI: 10.1016/S1098-3015(10)74349-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN72 GENE EXPRESSION PROFILING FOR GUID

PCN72 GENE EXPRESSION PROFILING FOR GUIDING ADJUVANT CHEMOTHERAPY DECISIONS IN WOMEN WITH EARLY BREAST CANCER: A COST-EFFECTIVENESS ANALYSIS OF 1000 STRATEGIES FOR THE PROVISION OF ADJUVANT! ONLINE, ONCOTYPE DX AND CHEMOTHERAPY

✍ M. Paulden; J. Franek; B. Pham; M. Krahn 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

PCN91 LONG TERM COST-EFFECTIVENESS OF DO

PCN91 LONG TERM COST-EFFECTIVENESS OF DOCETAXEL PLUS CYCLOPHOSPHAMIDE COMPARED TO DOXORUBICIN PLUS CYCLOPHOSPHAMIDE AS ADJUVANT TREATMENT FOR WOMEN WITH OPERABLE BREAST CANCER

✍ D Jackson; JM Lee; J Adams; A Gordois 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB

PCN92 The Cost-Effectiveness of Nanopart

PCN92 The Cost-Effectiveness of Nanoparticle Albumin-Bound Paclitaxel Compared to Solvent-Based Paclitaxel in Women with Metastatic Breast Cancer

✍ Vandewalle, B.; Almeida, J.; Félix, J.; Silva, M.J.; Luz, R. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

Cost-effectiveness of switching to exeme

Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer

✍ Nancy A. Risebrough; Shailendra Verma; Maureen Trudeau; Nicole Mittmann 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 1 views

## Abstract ## BACKGROUND. Sequential tamoxifen/exemestane therapy reportedly improves disease‐free survival in women with primary breast cancer compared with continued tamoxifen therapy. The objective of the current study was to assess the cost‐effectiveness of switching to exemestane after 2 to

PCN116 A SURVIVAL BASED COST-EFFECTIVENE

PCN116 A SURVIVAL BASED COST-EFFECTIVENESS ANALYSIS OF 5 YEARS LETROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER: CANADIAN PERSPECTIVE

✍ K El Ouagari; S Kaura; JD Karnon 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB

PCN9 PRIMARY PROPHYLAXIS OF FEBRILE NEUT

PCN9 PRIMARY PROPHYLAXIS OF FEBRILE NEUTROPENIA WITH PEGFILGRASTIM IS COST-EFFECTIVE COMPARED WITH SECONDARY PROPHYLAXIS FOR WOMEN WITH EARLYSTAGE BREAST CANCER RECEIVING CHEMOTHERAPY

✍ SD Ramsey; Z Liu; R Boer; JL Malin; SD Sullivan; QV Doan; RW Dubois; GH Lyman 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB